Thelansis

  Primary vitreoretinal lymphoma (PVRL) is a rare B-cell intraocular malignancy, commonly considered a subset of primary central nervous system (CNS) lymphoma. Brain dissemination occurs in 60–90% of patients, and it is the cause of the high mortality and morbidity of the disease. PVRL involves the vitreous, the retina, and the retinal pigment epithelium (RPE). According to the literature, around 15–20% of patients with primary central nervous system lymphoma (PCNSL) will develop PVRL later. The majority of PVRL is of B-cell origin. However, T-cell lymphomas and T-cell-rich lymphomas can also develop within the eye. PVRL has an approximate incidence in ~20% of patients with PCNSL and 0.03 to 0.1 cases per 100,000 people per year in the US. PVRL usually affects adults in the fifth-sixth decades of life. Thelansis’s “Primary Vitreoretinal Lymphoma (PVRL) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease ov...